share_log

Talaris Therapeutics (NASDAQ:TALS) Stock Rating Reaffirmed by HC Wainwright

kopsource ·  Feb 3, 2023 04:43

HC Wainwright reissued their buy rating on shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) in a research note published on Monday morning, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright also issued estimates for Talaris Therapeutics' Q4 2022 earnings at ($0.50) EPS, Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.51) EPS and FY2023 earnings at ($2.07) EPS.

Talaris Therapeutics Stock Up 2.3 %

NASDAQ TALS opened at $1.77 on Monday. The company has a market cap of $73.85 million, a price-to-earnings ratio of -1.07 and a beta of 2.36. Talaris Therapeutics has a 52 week low of $0.89 and a 52 week high of $10.56. The business has a 50 day moving average price of $1.27 and a 200-day moving average price of $2.37.

Get Talaris Therapeutics alerts:

Talaris Therapeutics (NASDAQ:TALS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, equities research analysts anticipate that Talaris Therapeutics will post -1.87 earnings per share for the current year.

Institutional Investors Weigh In On Talaris Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TALS. Two Sigma Investments LP purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $93,000. BNP Paribas Arbitrage SNC purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $64,000. Virtu Financial LLC purchased a new position in shares of Talaris Therapeutics during the second quarter valued at approximately $56,000. Commonwealth Equity Services LLC purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $34,000. Finally, Values First Advisors Inc. boosted its position in shares of Talaris Therapeutics by 29.9% during the fourth quarter. Values First Advisors Inc. now owns 39,891 shares of the company's stock valued at $41,000 after buying an additional 9,176 shares during the last quarter. Institutional investors own 65.43% of the company's stock.

Talaris Therapeutics Company Profile

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Featured Articles

  • Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
  • Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
  • Mullen Automotive Stock Gains Momentum On Positive News
  • Harley-Davidson Inc. Stock, Is It Time To Buy?
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment